Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ADPT
stocks logo

ADPT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
59.28M
+24.92%
-0.180
-20.91%
59.30M
+13.07%
-0.172
-14.17%
65.85M
+11.83%
-0.142
-16.66%
Estimates Revision
The market is revising Upward the revenue expectations for Adaptive Biotechnologies Corporation (ADPT) for FY2025, with the revenue forecasts being adjusted by 13.62% over the past three months. During the same period, the stock price has changed by 35.88%.
Revenue Estimates for FY2025
Revise Upward
up Image
+13.62%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-32.54%
In Past 3 Month
Stock Price
Go Up
up Image
+35.88%
In Past 3 Month
Wall Street analysts forecast ADPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADPT is 19.33 USD with a low forecast of 16.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast ADPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADPT is 19.33 USD with a low forecast of 16.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.460
sliders
Low
16.00
Averages
19.33
High
22.00
Current: 17.460
sliders
Low
16.00
Averages
19.33
High
22.00
Morgan Stanley
Tejas Savant
Equal Weight
maintain
$11 -> $16
2025-11-11
Reason
Morgan Stanley
Tejas Savant
Price Target
$11 -> $16
2025-11-11
maintain
Equal Weight
Reason
Morgan Stanley analyst Tejas Savant raised the firm's price target on Adaptive Biotechnologies to $16 from $11 and keeps an Equal Weight rating on the shares following the company's recent Q3 report.
JPMorgan
Rachel Vatnsdal
maintain
$17 -> $20
2025-11-06
Reason
JPMorgan
Rachel Vatnsdal
Price Target
$17 -> $20
2025-11-06
maintain
Reason
JPMorgan analyst Rachel Vatnsdal raised the firm's price target on Adaptive Biotechnologies to $20 from $17 and keeps an Overweight rating on the shares following the Q3 report.
Piper Sandler
Overweight
maintain
$15 -> $20
2025-10-15
Reason
Piper Sandler
Price Target
$15 -> $20
2025-10-15
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Adaptive Biotechnologies to $20 from $15 and keeps an Overweight rating on the shares. The firm notes it surveyed 59 doctors but focused on the 28 who see blood cancers. From its survey, Adaptive continues to stand out as an underappreciated stock in the MRD space, holding the second-highest revenues and volumes specifically linked to minimal residual disease detection, and serving the most covered lives. Piper believes the company has significant growth potential, projecting approximately 30% increases in both volume over the next few years, driven by expanded EMR adoption, recent strategic partnerships, blood-based testing options, and ongoing clinical trials.
Guggenheim
NULL -> Buy
initiated
$20
2025-09-30
Reason
Guggenheim
Price Target
$20
2025-09-30
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of Adaptive Biotechnologies with a Buy rating and $20 price target.
Guggenheim
initiated
$20
2025-09-30
Reason
Guggenheim
Price Target
$20
2025-09-30
initiated
Reason
Guggenheim initiated coverage of Adaptive Biotechnologies with a Buy rating and $20 price target. The company is and should remain the dominant provider of minimal residual disease blood cancer tests, the analyst tells investors in a research note. The firm sees a path for sustained revenue growth for Adaptive due to continued market conversion, penetration into different indications, and price increases. The shares trade at a "notable discount" to other leading cancer specialty lab companies, contends Guggenheim.
JPMorgan
Rachel Vatnsdal
Overweight
maintain
$10 -> $14
2025-08-06
Reason
JPMorgan
Rachel Vatnsdal
Price Target
$10 -> $14
2025-08-06
maintain
Overweight
Reason
JPMorgan analyst Rachel Vatnsdal raised the firm's price target on Adaptive Biotechnologies to $14 from $10 and keeps an Overweight rating on the shares following the Q2 report. The firm believes momentum in the minimal residual disease business positions Adaptive for a strong back half of the year.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Adaptive Biotechnologies Corp (ADPT.O) is -27.71, compared to its 5-year average forward P/E of -11.65. For a more detailed relative valuation and DCF analysis to assess Adaptive Biotechnologies Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.65
Current PE
-27.71
Overvalued PE
-1.45
Undervalued PE
-21.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-20.92
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.68
Undervalued EV/EBITDA
-46.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.14
Current PS
0.00
Overvalued PS
25.69
Undervalued PS
-1.42
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 176.86% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ADPT News & Events

Events Timeline

(ET)
2025-12-01
16:30:00
Morgan Stanley Initiates Coverage on Adaptive Biotechnologies with Equal Weight Rating and $21 Price Target
select
2025-11-24 (ET)
2025-11-24
07:42:05
Adaptive Biotechnologies to Present 90 Abstracts at ASH Conference
select
2025-11-21 (ET)
2025-11-21
12:00:44
Adaptive Biotechnologies Sees 11.3% Increase
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-02Yahoo Finance
Insider at Adaptive Biotechnologies Offloads Shares Valued at $3,070,747, Recent SEC Filing Reveals

  • CEO Stock Sale: Chad M Robins, the Director, CEO, and Chairman, sold 160,734 shares on November 26, 2025.

  • Portfolio Access: Users need to sign in to access their portfolio information.

[object Object]
Preview
3.5
11-24Newsfilter
Adaptive Biotechnologies Showcases 89 Abstracts at ASH Meeting Including 36 Oral Presentations
  • Rich Research Output: Adaptive Biotechnologies will present 89 abstracts on clonoSEQ® at the upcoming American Society of Hematology (ASH) Annual Meeting, including 36 oral presentations. These studies cover various blood cancers, showcasing clonoSEQ's extensive application and validation in MRD assessment.
  • Clinical Impact: Over 17 presentations demonstrate how clonoSEQ informs treatment decisions in real-world clinical practice, particularly in acute lymphoblastic leukemia and chronic lymphocytic leukemia. This highlights the critical role of MRD testing in modern hematologic oncology care.
  • Ongoing Technological Innovation: The use of clonoSEQ continues to expand in clinical trials, enabling deep assessments of treatment responses for novel therapies, including CAR T and bispecific antibodies. This advancement supports innovation in treatment protocols and enhances progress in blood cancer therapies.
  • Market Leadership: The Chief Commercial Officer of Adaptive Biotechnologies noted that the breadth of clonoSEQ presentations at ASH underscores the integral role of MRD testing in patient care and clinical research. This trend will further solidify the company's leadership position in the blood cancer sector.
[object Object]
Preview
9.5
11-22Benzinga
Ross Stores Reports Impressive Q3 Earnings, Alongside Enviri, Azenta, and Other Major Stocks Rising on Friday

  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones increasing by approximately 150 points on Friday.

  • Ross Stores Financial Results: Ross Stores Inc. reported better-than-expected third-quarter earnings of $1.58 per share and raised its FY25 GAAP EPS guidance, leading to a 6.3% increase in its stock price.

  • Significant Stock Gains: Enviri Corp saw a notable 29.1% rise in its shares after announcing a major sale, while other companies like Datavault AI Inc and Herbalife Ltd also recorded substantial gains.

  • Analyst Upgrades: WillScot Holdings Corp received an upgrade from Baird analyst Andrew Wittmann, boosting its stock price target from $20 to $22, contributing to a 10.4% increase in its shares.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Adaptive Biotechnologies Corp (ADPT) stock price today?

The current price of ADPT is 17.46 USD — it has increased 1.93 % in the last trading day.

arrow icon

What is Adaptive Biotechnologies Corp (ADPT)'s business?

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

arrow icon

What is the price predicton of ADPT Stock?

Wall Street analysts forecast ADPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADPT is 19.33 USD with a low forecast of 16.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Adaptive Biotechnologies Corp (ADPT)'s revenue for the last quarter?

Adaptive Biotechnologies Corp revenue for the last quarter amounts to 93.97M USD, increased 102.38 % YoY.

arrow icon

What is Adaptive Biotechnologies Corp (ADPT)'s earnings per share (EPS) for the last quarter?

Adaptive Biotechnologies Corp. EPS for the last quarter amounts to 0.06 USD, decreased -127.27 % YoY.

arrow icon

What changes have occurred in the market's expectations for Adaptive Biotechnologies Corp (ADPT)'s fundamentals?

The market is revising Upward the revenue expectations for Adaptive Biotechnologies Corporation (ADPT) for FY2025, with the revenue forecasts being adjusted by 13.62% over the past three months. During the same period, the stock price has changed by 35.88%.
arrow icon

How many employees does Adaptive Biotechnologies Corp (ADPT). have?

Adaptive Biotechnologies Corp (ADPT) has 619 emplpoyees as of December 05 2025.

arrow icon

What is Adaptive Biotechnologies Corp (ADPT) market cap?

Today ADPT has the market capitalization of 2.67B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free